EAM
AEGR

Eagle Asset Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Eagle Asset Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,060,633
Closed -$49M – 687
2014
Q1 		$49M Buy
1,060,633
+26,988
+3% +$1.58M 0.27% 128
2013
Q4 		$73.3M Buy
1,033,645
+399,160
+63% +$30.5M 0.41% 67
2013
Q3 		$53.7M Buy
+634,485
New +$53.8M 0.27% 114

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Eagle Asset Management's AEGR Position: Q2 2014 in Review

Eagle Asset Management sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 1,060,633 shares — an estimated $49M sold.

Eagle Asset Management first reported a position in AEGR in Q3 2013 and held it in 3 quarters. The position peaked at $73.3M in Q4 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • Eagle Asset Management reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Eagle Asset Management sold 1,060,633 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $49M.
  • Eagle Asset Management first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 3 quarters.
  • Eagle Asset Management's Aegerion Pharmaceuticals position peaked at $73.3M in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on Eagle Asset Management's 13F filing for Q2 2014, filed 10 Jul 2014.